Abstract | OBJECTIVE: METHODS: Adopting randomized non-blinded and parallel controlled trial, 200 patients with CHD were randomly and equally assigned to the SBP group and the control group. Both received basic therapy for CHD, including anti-platelet, lipid regulating and anti- ischemia with additional SBP 2 pills, taken orally three times per day in the SBP group. They were followed up for 6 months. The drug tolerability and adverse drug reactions occurred in the observation period were recorded, and the laboratory indexes involving blood routine, liver function, renal function, blood glucose and blood lipids were detected before and after treatment. RESULTS: The trial was completed in 92% of the patients, 5 patients withdrew in the SBP group and 11 patients in the control group; but none for the intolerable therapy. There were 1 case of adverse reaction related to SBP. No obvious change was found in blood glucose and blood lipids in the two groups before and after treatment. No serious adverse reaction and injury of liver and renal function or others happened. CONCLUSION: Long-term administration of SBP has favorable clinical tolerability and safety for CHD patients.
|
Authors | Li-Jie Wang, Xin-Ping Luo, Yong Wang |
Journal | Zhongguo Zhong xi yi jie he za zhi Zhongguo Zhongxiyi jiehe zazhi = Chinese journal of integrated traditional and Western medicine
(Zhongguo Zhong Xi Yi Jie He Za Zhi)
Vol. 28
Issue 5
Pg. 399-401
(May 2008)
ISSN: 1003-5370 [Print] China |
PMID | 18672763
(Publication Type: English Abstract, Journal Article, Randomized Controlled Trial)
|
Chemical References |
- Drugs, Chinese Herbal
- Tablets
- shexiang baoxin
|
Topics |
- Angina Pectoris
(drug therapy)
- Coronary Disease
(drug therapy)
- Drugs, Chinese Herbal
(administration & dosage, adverse effects, therapeutic use)
- Humans
- Medicine, Chinese Traditional
- Tablets
|